Cardiovascular Disease Risk After Treatment-Induced Premature Ovarian Insufficiency in Female Survivors of Hodgkin Lymphoma

• Published in: Journal of the American College of Cardiology Vol. 72; no. 25; pp. 3374 - 3375
• Main Authors: Krul, Inge M., Opstal–van Winden, Annemieke W.J., Janus, Cécile P.M., Daniëls, Laurien A., Appelman, Yolande, Maas, Angela H.E.M., de Vries, Simone, Jóźwiak, Katarzyna, Aleman, Berthe M.P., van Leeuwen, Flora E.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 25.12.2018; Elsevier Limited
• Subjects: Age; Aging; Cardiology; Cardiovascular; Cardiovascular disease; Cardiovascular diseases; Health risk assessment; Heart; Hodgkin's lymphoma; Hormone replacement therapy; Hypotheses; Lymphoma; Menopause; Reproductive status; Risk factors; Womens health
• ISSN: 0735-1097; 1558-3597; 1558-3597
• DOI: 10.1016/j.jacc.2018.10.030

[...]unfavorable CVD risk factors may determine menopausal age (3), or third, POI and CVD may both be due to a (gene-related) generalized aging process or shared risk factors (4). If ovarian hormone deficiency causes CVD, we expect to find increased risk of CVD after treatment-induced POI in HL survivors, whereas CVD risk would not be increased if the alternative hypotheses are true. Because female HL survivors are already at increased risk of CVD due to the cardiotoxicity of HL treatment, it is important to know whether POI is an additional risk factor that should be incorporated into screening guidelines. [...]treatment-induced POI and duration of post-treatment intact ovarian function did not affect CVD risk in HL survivors, suggesting that an early artificial menopause does not increase CVD risk.